Compare EPM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | VRCA |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.9M | 137.3M |
| IPO Year | 1996 | 2018 |
| Metric | EPM | VRCA |
|---|---|---|
| Price | $4.16 | $5.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.83 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 324.3K | 35.3K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,229,621.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $3.19 | $0.52 |
| 52 Week High | $5.70 | $9.82 |
| Indicator | EPM | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 44.47 |
| Support Level | $4.13 | $5.27 |
| Resistance Level | $4.63 | $6.48 |
| Average True Range (ATR) | 0.14 | 0.49 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 26.92 | 19.17 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.